Patricia Galván

Research group

Translational genomics and targeted therapies in solid tumours Technician

galvan@recerca.clinic.cat 0000-0002-8153-0307

Featured publications

A predictive model of pathological response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade.

Authors:
Nuciforo P; Pascual T; Cortés J; Llombart-Cussac A; Fasani R;

(...)

Rodrik-Outmezguine V; Brase JC; Villagrasa P; Prat A; Holgado E .

Reference: Annals Of Oncology 2018.
Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma.

Authors:
Prat A; Navarro A; Paré L; Reguart N; Galván P;

(...)

Victoria I; Viñolas N; Vivancos A; Arance A; Felip E .

Reference: Cancer Research 2017.
Resistance to Taxanes in Triple-Negative Breast Cancer Associates with the Dynamics of a CD49f+ Tumor-Initiating Population

Authors:
Gómez-Miragaya J.; Palafox M.; Paré L.; Yoldi G.; Ferrer I.;

(...)

Soler-Monso M.; Petit A.; Serra V.; Prat A.; González-Suárez E..

Reference: Stem Cell Reports 2017.
Intrinsic subtypes and gene expression profiles in primary and metastatic breast cancer.

Authors:
Cejalvo JM; Martínez de Dueñas E; Galván P; García-Recio S; Burgués Gasión O;

(...)

Adamo V; Albanell J; Gomis RR; Lluch A; Prat A .

Reference: Cancer Research 2017.
HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): An open-label, single-group, multicentre, phase 2 trial

Authors:
Llombart-Cussac, Antonio; Cortes, Javier; Pare, Laia; Galvan, Patricia; Bermejo, Begona;

(...)

Morales, Serafin; Oliveira, Mafalda; de la Pena, Lorena; Pelaez, Alexandra; Prat, Aleix.

Reference: Lancet Oncology 2017.
Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2- negative breast cancer

Authors:
Fernandez-Martinez, Aranzazu; Pascual, Tomas; Perrone, Giuseppe; Morales, Serafin; de la Haba, Juan;

(...)

Carrasco, Eva; Altomare, Vittorio; Tonini, Giuseppe; Prat, Aleix; Martin, Miguel.

Reference: Oncotarget 2017.
Identification of ALK, ROS1 and RET Fusions by a Multiplexed mRNA-Based Assay in Formalin-Fixed, Paraffin-Embedded Samples from Advanced Non-Small-Cell Lung Cancer Patients.

Authors:
Reguart N; Teixidó C; Giménez-Capitán A; Paré L; Galván P;

(...)

Merkelbach-Bruse S; Büttner R; Rosell R; Molina-Vila MA; Prat A .

Reference: Clinical Chemistry 2017.
Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib

Authors:
Prat, Aleix; Cheang, Maggie C. U.; Galvan, Patricia; Nuciforo, Paolo; Pare, Laia;

(...)

Viladot, Margarida; Press, Michael F.; Gagnon, Robert; Ellis, Catherine; Johnston, Stephen;.

Reference: Jama Oncology 2016.
Intrinsic subtype and gene expression changes between primary and metastatic breast cancer

Authors:
Prat, A; Martinez de Dunas, E; Galvan, P; Garcia, S; Burgues, O;

(...)

Perou, C M; Cortes, J; Adamo, V; Albanell, J; Lluch, A.

Reference: Cancer Research 2016.
Efficacy and gene expression results from eribulin SOLTI1007 neoadjuvant study

Authors:
Prat, A.; Ortega, V.; Pare, L.; Galvan, P.; Oliveira, M.;

(...)

di Cosimo, S.; Rubio, I. T.; Harbeck, N.; Baselga, J.; Cortes, J.;.

Reference: Cancer Research 2016.

Featured Projects

Estudio prospectivo exploratorio para la determinación de DNA circulante tumoral (ctDNA) en muestras sanguíneas de pacientes tratadas por cáncer de mama en seguimiento y sin evidencia de recidiva: ESTUDIO B-CRONOS

Duration: 01/01/2018 - 01/01/2021
Estudio prospectivo exploratorio para la determinación de DNA circulante tumoral (ctDNA) en muestras sanguíneas de pacientes tratadas por cáncer de mama en seguimiento y sin evidencia de recidiva: ESTUDIO B-CRONOS

Duration: 01/01/2018 - 01/01/2021
Doble bloque Her2 sin quimioterapia en cáncer de mama precoz Her2+

Duration: 01/01/2017 - 01/01/2019
FERP - Construcción y evaluación de linfocitos T con un receptor quimérico antigénico (CART) anti-HER2 para el tratamiento de tumores sólidos HER2-positivos

Duration: 01/01/2016 - 01/01/2017
BCRF - Financial Support for the Breast Cancer Intergroup Correlative Science Studies

Duration: 01/10/2014 - 30/09/2016

Patricia Galván

Research group

Featured publications

Featured Projects

Estudio prospectivo exploratorio para la determinación de DNA circulante tumoral (ctDNA) en muestras sanguíneas de pacientes tratadas por cáncer de mama en seguimiento y sin evidencia de recidiva: ESTUDIO B-CRONOS

Estudio prospectivo exploratorio para la determinación de DNA circulante tumoral (ctDNA) en muestras sanguíneas de pacientes tratadas por cáncer de mama en seguimiento y sin evidencia de recidiva: ESTUDIO B-CRONOS

Doble bloque Her2 sin quimioterapia en cáncer de mama precoz Her2+

FERP - Construcción y evaluación de linfocitos T con un receptor quimérico antigénico (CART) anti-HER2 para el tratamiento de tumores sólidos HER2-positivos

BCRF - Financial Support for the Breast Cancer Intergroup Correlative Science Studies

Subscribe to the Newsletter of Clínic